Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Cogent Biosciences, Inc. | umrx-ex321_121.htm |
| EX-31.2 - EX-31.2 - Cogent Biosciences, Inc. | umrx-ex312_123.htm |
| EX-31.1 - EX-31.1 - Cogent Biosciences, Inc. | umrx-ex311_124.htm |
| EX-10.3 - EX-10.3 - Cogent Biosciences, Inc. | umrx-ex103_142.htm |
| 10-Q - 10-Q - Cogent Biosciences, Inc. | umrx-10q_20200331.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Unum Therapeutics Inc. (the “Company”) for the period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Matthew Osborne, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: May 11, 2020 |
By: |
|
/s/ Matthew Osborne |
|
|
|
|
Matthew Osborne |
|
|
|
|
Chief Financial Officer (Principal Financial Officer) |